This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research. 2019;20(1): 13.Search in Google Scholar
Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Therapeutic Advances in Respiratory Disease. 2017;11(8): 327–340.Search in Google Scholar
Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. The European Respiratory Review. 2013;22(127): 6–19.Search in Google Scholar
Mango R, Ryu J, Makol A. Newer insights into the management of interstitial lung disease in systemic sclerosis. Indian Journal of Rheumatology. 2107;12: S194–S203.Search in Google Scholar
Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmunity Reviews. 2011;10(5): 248–255.Search in Google Scholar
Luo Y, Xiao R. Interstitial lung disease in scleroderma: clinical features and pathogenesis. Rhematology. 2011;S1(2): 1–5.Search in Google Scholar
Jain S, Shahane A, Derk CT. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy. Inflammation & Allergy-Drug Targets. 2012;11(4): 266–277.Search in Google Scholar
Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Current Rheumatology Reports. 2014;16(4): 411.Search in Google Scholar
Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Aetiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6): 650–660.Search in Google Scholar
Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Review of Clinical Immunology. 2019;15(7): 753–764.Search in Google Scholar
Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nature reviews. Disease Primers. 2015;1: 15002.Search in Google Scholar
Ahmed S, Pattanaik S, Rai M, Nath A, Agarwal V. Interstitial lung disease in systemic sclerosis: insight into pathogenesis and evolving therapies. Mediterranean Journal of Rheumatology. 2018;29(3): 140–147.Search in Google Scholar
Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases. 2015;74(6): 1188–1194.Search in Google Scholar
Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. The Lancet. RespiratoryMedicine. 2020;8(3): 304–320.Search in Google Scholar
Soldano S, Trombetta AC, Contini P, Tomatis V, Ruaro B, Brizzolara R, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Annals of the Rheumatic Diseases. 2018;77(12): 1842–1845.Search in Google Scholar
Trombetta AC, Soldano S, Contini P, Tomatis V, Ruaro B, Paolino S, et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respiratory Research. 2018;19(1): 186.Search in Google Scholar
Veraldi KL, Hsu E, Feghali-Bostwick CA. Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Current Rheumatology Reports. 2010;12(1): 19–25.Search in Google Scholar
Volkmann ER, Tashkin DP. Treatment of systemic sclerosis- related interstitial lung disease: a review of existing and emerging therapies. Ann The American Thoracic Society. 2016;13(11): 2045–2056.Search in Google Scholar
Wells AU. Interstitial lung disease in systemic sclerosis. Presse Medicale. 2014;43(10 Pt 2): e329–e343.Search in Google Scholar
Chowaniec M, Skoczynska M, Sokolik R, Wiland P. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia 2018;56(4): 249–254.Search in Google Scholar
Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? European Respiratory Review. 2015;24(137): 411–419.Search in Google Scholar
Branley H. Pulmonary fibrosis in systemic sclerosis: diagnosis and management. Respiratory Medicine CME. 2010;3: 10–14.Search in Google Scholar
Bonifazi M, Sverzellati N, Negri E, Jacob J, Egashira R, Moser J, et al. Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. The European Respiratory Journal. 2020;56(1): 1902135.Search in Google Scholar
Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. American Journal of Respiratory and Critical Care Medicine. 2008;177(11): 1248–1254.Search in Google Scholar
Hoffmann-Vold A-M, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology. 2020;2(2): e71–e83.Search in Google Scholar
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. The New England Journal of Medicine. 2006;354(25): 2655–2666.Search in Google Scholar
Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. Journal of Scleroderma and Related Disorders. 2020;5 (2 Suppl): 61–71.Search in Google Scholar
Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis & Rheumatology. 2006;54(12): 3962–3970.Search in Google Scholar
Ueda T, Sakagami T, Kikuchi T, Takada T. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Respiratory Investigation. 2018;56(1): 14–20.Search in Google Scholar
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. The Lancet Respiratory Medicine. 2016;4(9): 708–719.Search in Google Scholar
Baqir M, Makol A, Osborn TG, Bartholmai BJ, Ryu JH. Mycophenolate mofetil for scleroderma-related interstitial lung disease: a real world experience. PLoS One. 2017;12(5): e0177107.Search in Google Scholar
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. The New England Journal of Medicine. 2019;380(26): 2518–2528.Search in Google Scholar
Hayton C, Chaudhuri N. Current treatments in the management of idiopathic pulmonary fibrosis: pirfenidone and nintedanib. Clinical Medicine Insights: Therapeutics. 2017;9: 1–4.Search in Google Scholar
Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020;40(5): 703–710.Search in Google Scholar
Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. The Journal of Rheumatology. 2016;43(9): 1672–1679.Search in Google Scholar
Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12): 2106–2113.Search in Google Scholar
Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038): 2630–2640.Search in Google Scholar
Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSS-cinate). Annals of the Rheumatic Diseases. 2018;77(2): 212–220.Search in Google Scholar
Narváez J, LLuch J, Alegre Sancho JJ, Molina-Molina M, Nolla JM, Castellví I. Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated inter-stitial lung disease: a case series. Annals of the Rheumatic Diseases. 2019;78(11): e123.Search in Google Scholar
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24): 2490–2498.Search in Google Scholar
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. The New England Journal of Medicine. 2018;378(1): 35–47.Search in Google Scholar
Chan EY, Goodarzi A, Sinha N, Nguyen DT, Youssef JG, Suarez EE, et al. Long-term survival in bilateral lung transplantation for scleroderma-related lung disease. The Annals of Thoracic Surgery. 2018;105(3): 893–900.Search in Google Scholar
Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. The Journal of Heart and Lung Transplantation. 2018;37(7): 903–911.Search in Google Scholar